tradingkey.logo

Incyte Q4 revenue growth beats estimates on demand for Jakafi

ReutersFeb 10, 2026 12:07 PM


Overview

  • Biopharmaceutical firm's Q4 revenue rose 28% yr/yr, beating analyst expectations

  • Adjusted EPS for Q4 missed analyst expectations

  • Company's revenue growth driven by demand for Jakafi and Opzelura


Outlook

  • Incyte projects 2026 total net product revenue between $4.77 bln and $4.94 bln

  • Company expects Jakafi net product revenue of $3.22 bln to $3.27 bln in 2026

  • Incyte anticipates Opzelura net product revenue of $750 mln to $790 mln in 2026


Result Drivers

  • PRODUCT DEMAND - Increased demand for Jakafi and Opzelura drove net product revenue growth in Q4 2025

  • NEW PRODUCT UPTAKE - Strong uptake of Niktimvo and Zynyz contributed to revenue growth

  • MILESTONE REVENUE - Milestone and contract revenue added $100 mln to Q4 total revenue


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Beat

$1.51 bln

$1.35 bln (20 Analysts)

Q4 Adjusted EPS

Miss

$1.80

$1.93 (17 Analysts)

Q4 EPS

$1.46

Q4 Adjusted Operating Income

Miss

$451.42 mln

$473.06 mln (10 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 14 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Incyte Corp is $108.50, about 0.5% below its February 9 closing price of $109.03

  • The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 12 three months ago

Press Release: ID:nBwbbn8FRa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI